人表皮生长因子受体3在乳腺癌组织中的表达及临床意义

目的探讨人表皮生长因子受体(HER)3基因在乳腺癌组织中的表达及其与临床病理学特征和预后的相关性。方法采用免疫组织化学法检测126例乳腺癌组织中HER3的表达,分析其表达与患者年龄、月经情况、TNM分期、肿瘤大小、淋巴结转移、雌激素受体(ER)、孕激素受体(PR)、HER2及预后的关系。结果 (1)乳腺癌组织中HER3的阳性表达率为30.2%。HER3阳性表达在乳腺癌绝经患者中占43.3%,高于未绝经者的18.2%(P0.05);淋巴结转移阳性的乳腺癌患者HER3阳性表达率为40.0%,高于无淋巴结转移患者的21.2%,差异有统计学意义(P0.05);HER2阳性的乳腺癌患者HER3阳性表达率为42.5%,高于HER2阴性者的24.4%,差异有统计学意义(P0.05)。(2)HER3阳性患者的五年无病生存率更低(P0.05)。(3)HER3与HER2均阳性的乳腺癌患者淋巴结转移率较高(P0.05)。结论 HER3的表达可能在乳腺癌的发生和发展过程中起重要作用,并影响其预后,HER3可能成为判断乳腺癌预后的指标及临床治疗的靶点。

Expression and clinical significance of HER3 in breast carcinoma tissue

Objective To investigate the expression of human epithelial growth factor receptor-3(HER3) in breast cancer tissue and its correlation with clinicopathological characteristics and prognosis .Methods The immuno-histochemical method was used to detect the HER3 expression in 126 specimens of breast cancer tissue .The relation between its expression with age ,menstruation situation ,tumor size ,TNM stage ,lymph node metastasis ,estrogen receptor(ER) ,progesterone receptor(PR) ,HER2 and prognosis was analyzed .Results (1)The positive expression rate of HER3 in breast cancer tissue was 30 .2% .The HER3 positive expression in the breast cancer menopausal pa-tients was 43 .3% ,which was higher than 18 .2% in the non-menopausal ones(P<0 .05) ,and the HER3 positive expression in the patients with positive lymph nodes metastasis was 40 .0% ,which was higher than 21 .2% in the non-lymph node metastasis ones ,the differences were statistically significant(P<0 .05);and the HER3 positive ex-pression in the breast cancer patients with HER2 positive was 42 .5% ,which was higher than 24 .4% in the patients with non-HER2 positive ,the difference was statistically significant(P<0 .05) .(2) The 5-year disease-free survival (DFS) rate in the HER3 positive patients was lower (P<0 .05) .(3) The lymph node metastasis rate in the patients with both HER3 and HER2 positive was significantly higher (P<0 .05) .Conclusion The HER3 expression plays an important role in the development of breast cancer and influences its prognosis ,therefore HER3 could be used as an indicator for judging the prognosis of breast cancer and a target point of clinical therapy .